vaccine against equine strangles Strangvac

Validation batches of the vaccine against equine strangles Strangvac® is completed

28 January, 2020 | General

3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics has, together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against equine strangles called Strangvac®. The validation production batches required for the forthcoming registration application to the European Medicines […]

The manufacturing process for Strangvac, the new vaccine against equine strangles, is proceeding according to plan

27 August, 2019 | General

The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, finalized the production of the drug substances on a commercial scale in compliance with GMP (Good Manufacturing Practice). “We are very pleased to announce that we have now manufactured the drug substances for several million doses of Strangvac, the new vaccine […]

Large-scale manufacturing process for Strangvac now secured

2 April, 2019 | General

We are so glad to be part of such an exciting project with the Swedish company INTERVACC, who we are working with on manufacturing of Strangvac® including the large-scale production of the vaccine against equine strangles. The biotechnology company Intervacc has together with 3P Biopharmaceuticals, the contracted manufacturer of Strangvac, secured large-scale production of the […]